Stereotactic Radioablation as First-Line Therapy for Scar-Related Ventricular Tachycardia

NCT07618780 | Not Yet Recruiting DMC

• 1 other identifier: S-041-2425
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Ventricular tachycardia (VT) is a dangerous fast heart rhythm originating from scarred areas of the heart muscle, often after a heart attack or in patients with cardiomyopathy. Patients with VT and structural heart disease typically receive an implantable cardioverter-defibrillator (ICD) to prevent sudden death. Despite the ICD, recurrent VT and ICD shocks remain common and are associated with poor quality of life. Current preventive therapies - antiarrhythmic medications and catheter radiofrequency ablation - have important limitations including side effects, incomplete effectiveness, and procedural risk. Stereotactic Arrhythmia Radioablation (STAR) is a non-invasive treatment in which a single, precisely targeted dose of radiation is delivered to the scar tissue that gives rise to the abnormal heart rhythm. STAR has previously been studied in patients who have failed catheter ablation or are too high risk for that procedure, with promising results. However, STAR has not been formally evaluated as a first-line treatment. This single-arm prospective feasibility study will enroll 20 adults with structural heart disease and sustained monomorphic VT. Each participant will receive a single 25 Gy fraction of stereotactic body radiotherapy (VMAT technique) targeted at the arrhythmogenic substrate identified by cardiac imaging, 12-lead ECG, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. Participants will be followed at 6 weeks, 3, 6, 9, and 12 months to assess the primary efficacy outcomes (death, appropriate ICD shock, VT storm, and sustained VT below ICD detection rate after a 6-week blanking period) and safety outcomes (acute heart failure decompensation, drop in left ventricular ejection fraction, and STAR-specific toxicities such as pneumonitis, esophagitis, and pericarditis). The hypothesis is that STAR delivered as first-line therapy is safe and effective, with a comparable toxicity and efficacy profile to catheter radiofrequency ablation.

Conditions

Ventricular Tachycardia, Monomorphic; Cardiomyopathies

Keywords

Stereotactic Body Radiotherapy; Cardiac Radioablation; Radioablation; Implantable Cardioverter Defibrillator; STAR-VT

Outcome Measures

Primary Outcomes (2)

• Composite of death, appropriate ICD shock, VT storm, or sustained VT below ICD detection (after 6-week blanking period)

  Proportion of participants experiencing at least one of the following events after the 6-week post-treatment blanking period: (1) death from any cause; (2) appropriate ICD shock; (3) VT storm, defined as \>3 episodes of VT within 24 hours; or (4) sustained VT below the ICD detection rate requiring external cardioversion, pharmacologic conversion, or manual ICD cardioversion (shock or ATP). ICDs will be interrogated at every device-clinic visit.

  From 6 weeks post-treatment through 12 months follow-up

• Safety: Composite of serious adverse events related to STAR

  Proportion of participants experiencing any of the following: (1) acute worsening of heart failure requiring initiation of new IV vasoactive medications (inotropes or vasopressors) within the first 6 weeks; (2) acute reduction in left ventricular ejection fraction greater than 10 percentage points within the first 6 weeks; (3) any STAR-specific symptom including esophagitis, pneumonitis, or pericarditis assessed by CTCAE v5. The pre-specified safety threshold is a serious adverse event rate of \<=20%.

  Acute (<6 weeks post-treatment) and late (up to 6 months post-treatment)

Secondary Outcomes (2)

• Change in ventricular tachycardia burden

  Baseline (6 months prior to treatment) through 12 months post-treatment

• Hospital admissions for cardiac or radiation-related causes

  From treatment through 12 months follow-up

Study Arms (1)

STAR (Stereotactic Arrhythmia Radioablation)

EXPERIMENTAL

Single 25 Gy fraction of VMAT-based stereotactic body radiotherapy delivered to the arrhythmogenic substrate identified by cardiac CT, 12-lead ECG of the clinical arrhythmia, and (where available) non-invasive electrocardiographic mapping or electroanatomical mapping. In selected cases with large planning target volumes or proximity to organs at risk, the dose may be delivered in 2 fractions 24-48 hours apart. Participants are followed for 12 months for arrhythmia outcomes and radiation toxicity.

Radiation: Stereotactic Arrhythmia Radioablation

Interventions

Stereotactic Arrhythmia Radioablation RADIATION

Single fraction of 25 Gy stereotactic body radiotherapy (SBRT) delivered using a volumetric modulated arc therapy (VMAT) technique with 6 MV FFF photons on an Elekta Agility linear accelerator. The clinical target volume (arrhythmogenic scar) is delineated by the radiation oncologist and electrophysiologist using cardiac CT, 12-lead ECGs of the clinical arrhythmia, and (where available) non-invasive electrocardiographic mapping (252-electrode CardioInsight vest) and/or 3-D electroanatomical mapping. A 4D-CT simulation accounts for cardiac and respiratory motion. In selected cases with a large planning target volume or proximity to critical organs at risk (stomach, esophagus, spinal cord), the dose may be delivered in 2 fractions 24-48 hours apart. Treatment is delivered with image guidance (cone-beam CT) on the day of treatment. Total dose: 25 Gy in 1 or 2 fractions.

Also known as: Cardiac SBRT

STAR (Stereotactic Arrhythmia Radioablation)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age 18 years or older and able to provide informed consent
• Structural heart disease with myocardial fibrosis identified on pre-procedural imaging, including imaging evidence of regional myocardial akinesis/thinning or documented scar on echocardiography, cardiac CT, or cardiac MRI
• Sustained monomorphic ventricular tachycardia (symptomatic or requiring ICD shocks for termination) within the previous 6 months

You may not qualify if:

• Reversible causes of VT (e.g., active ischemia, drug-induced, electrolyte abnormalities)
• Acute coronary syndrome within 30 days, coronary revascularization (\<90 days for bypass surgery, \<30 days for percutaneous coronary intervention)
• Patients previously treated with high-dose radiotherapy that precludes safe delivery of thoracic stereotactic radiotherapy (relative contraindication)
• Patients requiring chest radiotherapy for an active cancer (relative contraindication)
• VT targets cannot be identified or are not suitable for targeting with stereotactic radiotherapy (such as multiple foci of arrhythmia)
• Patients who cannot tolerate the radiotherapy treatment position, or whose body habitus is not permissible by treatment bed requirements
• Pregnant or breast-feeding women
• Patients being considered for cardiac transplant who are deemed not eligible by their transplant team for STAR

Sponsors & Collaborators

• Southlake Health: lead

Study Sites (1)

Southlake Regional Health Centre

Newmarket, Ontario, L3Y 2P9, Canada

Location

MeSH Terms

Conditions

Tachycardia, Ventricular; Cardiomyopathies

Condition Hierarchy (Ancestors)

Tachycardia; Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Cardiac Conduction System Disease; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Mouhannad Sadek, MD

CONTACT

905-895-4521; msadek@southlake.ca

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: May 24, 2026
• First Posted: June 1, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2029
• Study Completion (Estimated): July 1, 2029
• Last Updated: June 1, 2026

Record last verified: 2026-05

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)